Vera Therapeutics, Inc.

NasdaqGM VERA

Vera Therapeutics, Inc. Receivables for the quarter ending September 30, 2024

Vera Therapeutics, Inc. Receivables is NA for the quarter ending September 30, 2024. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Vera Therapeutics, Inc. Receivables for the quarter ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Vera Therapeutics, Inc. Receivables for the quarter ending September 30, 2022 was USD 0.00.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqGM: VERA

Vera Therapeutics, Inc.

CEO	Dr. Marshall W. Fordyce M.D.
IPO Date	May 14, 2021
Location	United States
Headquarters	8000 Marina Boulevard
Employees	82
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Key trends

Past 5 years